TYPHIM Vi is indicated for active immunisation against typhoid fever caused by Salmonella enterica serovar typhi , S.typhi in adults and children 2 years of age or older.
GlaxoSmithKline and Innoviva announced positive headline results from the landmark phase III IMPACT study of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, FF/UMEC/VI)...
The study evaluates the efficacy of fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with COPD.
The FDA has approved Breo Ellipta (fluticasone furoate/vilanterol [FF/VI]), from Glaxo Smith Kline, for the once-daily treatment of asthma in...
Positive results from a third lung function study comparing the efficacy and safety of Anoro Ellipta (umeclidinium /vilanterol, �UMEC/VI�), from...
GlaxoSmithKline and Innoviva announced positive data from a study comparing Anoro Ellipta (umeclidinium/vilanterol 62.5mcg/25mcg; UMEC/VI) and Stiolto Respimat (tiotropium/olodaterol 5mcg/5mcg;...
GlaxoSmithKline plc (GSK) and Theravance, Inc. have announced the submission of a regulatory application in the US for the investigational...
GlaxoSmithKline and Innoviva announced headline results from the pivotal phase III CAPTAIN study of once-daily single inhaler triple therapy Trelegy...
GlaxoSmithKline plc and Innoviva, Inc. announced the filing of a supplemental New Drug Application (sNDA) with the FDA for the...
GlaxoSmithKline plc and Innoviva, Inc. announced that the FDA has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), under...